Sotalol vs Amiodarone — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Antiarrhythmic

Sotalol

Brand: BETAPACE

First FDA approval: 2000-05-04

Antiarrhythmic

Amiodarone

Brand: Nexterone

First FDA approval: 2001-03-30

Lowest NADACAcquisition cost floor across all NDCs

$0.070Per unit

$0.121Per unit

Average NADACAcross all dosage forms and strengths

$0.165Up to $2.31

$0.272Up to $0.789

Generic manufacturersActive ANDA holders — FDA Orange Book

731 total ANDAs filed

1527 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$36.3MFull year

$116.4MFull year

Part D claims (CY24)Total fills, all strengths

1.7M526K beneficiaries

4.8M1.6M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$21Per claim, all NDCs

$24Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1Minimal friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

Yes15 manufacturers